CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion

  • Posted by: BIOCON

University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)

Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society
  • Posted by: BIOCON

Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

  • Posted by: BIOCON

Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr

  • Posted by: BIOCON

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

  • Posted by: BIOCON

Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval

  • Posted by: BIOCON

Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East

  • Posted by: BIOCON

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

  • Posted by: BIOCON

Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>